539. Efficacy in Multiple SARS-CoV-2 Animal Models Supports Phase 3 Dose Selection for Obeldesivir

BACKGROUND: Remdesivir (RDV, Veklury) is the first FDA-approved direct-acting antiviral treatment for COVID-19. While RDV requires IV administration, obeldesivir (ODV, GS-5245) is an oral prodrug of GS-441524, the parent nucleoside of RDV, designed for effective oral delivery. ODV is being tested in...

Descripción completa

Detalles Bibliográficos
Autores principales: Pitts, Jared, Babusis, Darius, Humeniuk, Rita, Martinez, David, Cox, Robert M, Schäfer, Alexandra, Riola, Nicholas C, Feng, Joy, Du Pont, Venice, Anoshchenko, Olena, Vermillion, Meghan, Abdelghany, Mazin, Hyland, Robert H, Girish, Sandhya, Sheahan, Timothy P, Plemper, Richard K, Baric, Ralph S, Cihlar, Tomas, Llewellyn, Joe, Winter, Helen, Bannister, Roy, Subramanian, Raju, Mackman, Richard L, Bilello, John P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678974/
http://dx.doi.org/10.1093/ofid/ofad500.608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678974/
http://dx.doi.org/10.1093/ofid/ofad500.608

Ejemplares similares